Advances in Clinical NK Cell Studies: Donor Selection, Manufacturing and Quality Control

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2016 May 4

PMID 27141397

Citations 55

Authors

U Koehl

C Kalberer

J Spanholtz

D A Lee

J S Miller

S Cooley

M Lowdell

L Uharek

H Klingemann

A Curti

W Leung

E Alici

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013-2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.

Citing Articles

Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.

PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.

Ding J, Yeong C Front Oncol. 2024; 14:1504139.

PMID: 39703856 PMC: 11655346. DOI: 10.3389/fonc.2024.1504139.

In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy.

Qu J, Wang Y, Xiong C, Wang M, He X, Jia W Nat Commun. 2024; 15(1):10218.

PMID: 39587061 PMC: 11589603. DOI: 10.1038/s41467-024-54292-0.

Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34 cells and PD-L1 CAR-modified UCB-CD34-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.

Ghaedrahmati F, Akbari V, Seyedhosseini-Ghaheh H, Esmaeil N Stem Cell Res Ther. 2024; 15(1):257.

PMID: 39135206 PMC: 11321137. DOI: 10.1186/s13287-024-03871-5.

Generation of non-genetically modified, CAR-like, NK cells.

Coenon L, Rigal E, Courot H, Multrier C, Zemiti S, Lambour J J Immunother Cancer. 2024; 12(7).

PMID: 39029925 PMC: 11261687. DOI: 10.1136/jitc-2024-009070.

References

Yoon S, Lee Y, Yang S, Ahn K, Lee J, Lee J . Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2009; 45(6):1038-46. DOI: 10.1038/bmt.2009.304. View

Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess S . IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One. 2011; 6(11):e27351. PMC: 3212563. DOI: 10.1371/journal.pone.0027351. View

Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H . A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006; 12(20 Pt 1):6079-86. DOI: 10.1158/1078-0432.CCR-06-0114. View

Cany J, Dolstra H, Shah N . Umbilical cord blood-derived cellular products for cancer immunotherapy. Cytotherapy. 2015; 17(6):739-748. DOI: 10.1016/j.jcyt.2015.03.005. View

Luhm J, Brand J, Koritke P, Hoppner M, Kirchner H, Frohn C . Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res. 2002; 11(4):651-7. DOI: 10.1089/15258160260194794. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B . Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2010; 1(5):753-64. DOI: 10.2217/imt.09.47. View

Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner H, Tonn T . IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004; 33(3):261-6. DOI: 10.1016/j.bcmd.2004.08.013. View

Klingemann H . Challenges of cancer therapy with natural killer cells. Cytotherapy. 2014; 17(3):245-9. DOI: 10.1016/j.jcyt.2014.09.007. View

10.

Bachanova V, Burns L, McKenna D, Curtsinger J, Panoskaltsis-Mortari A, Lindgren B . Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010; 59(11):1739-44. PMC: 4082975. DOI: 10.1007/s00262-010-0896-z. View

11.

Glienke W, Esser R, Priesner C, Suerth J, Schambach A, Wels W . Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015; 6:21. PMC: 4325659. DOI: 10.3389/fphar.2015.00021. View

12.

Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T . Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009; 69(9):4010-7. PMC: 2716664. DOI: 10.1158/0008-5472.CAN-08-3712. View

13.

Locatelli F, Pende D, Mingari M, Bertaina A, Falco M, Moretta A . Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol. 2013; 4:15. PMC: 3561663. DOI: 10.3389/fimmu.2013.00015. View

14.

Cooper M, Elliott J, Keyel P, Yang L, Carrero J, Yokoyama W . Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009; 106(6):1915-9. PMC: 2644138. DOI: 10.1073/pnas.0813192106. View

15.

Berg M, Lundqvist A, McCoy Jr P, Samsel L, Fan Y, Tawab A . Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009; 11(3):341-55. PMC: 2736058. DOI: 10.1080/14653240902807034. View

16.

Klingemann H . Are natural killer cells superior CAR drivers?. Oncoimmunology. 2014; 3:e28147. PMC: 4203506. DOI: 10.4161/onci.28147. View

17.

Tam Y, Martinson J, Doligosa K, Klingemann H . Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy. 2003; 5(3):259-72. DOI: 10.1080/14653240310001523. View

18.

Ullrich E, Koch J, Cerwenka A, Steinle A . New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013; 2(10):e26097. PMC: 3862635. DOI: 10.4161/onci.26097. View

19.

Leung W . Use of NK cell activity in cure by transplant. Br J Haematol. 2011; 155(1):14-29. DOI: 10.1111/j.1365-2141.2011.08823.x. View

20.

Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T . Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011; 6(6):e20740. PMC: 3116834. DOI: 10.1371/journal.pone.0020740. View